Insider Selling: Scholar Rock (NASDAQ:SRRK) Insider Sells $257,895.04 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Jing Marantz sold 5,798 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $44.48, for a total transaction of $257,895.04. Following the completion of the sale, the insider owned 95,687 shares in the company, valued at $4,256,157.76. This represents a 5.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Scholar Rock Stock Down 7.3%

Shares of NASDAQ:SRRK opened at $44.29 on Friday. The company has a 50 day moving average price of $43.73 and a two-hundred day moving average price of $37.30. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. The company has a market capitalization of $4.52 billion, a PE ratio of -14.06 and a beta of 0.63. Scholar Rock Holding Corporation has a 52 week low of $22.71 and a 52 week high of $48.28.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period in the prior year, the company earned ($0.66) EPS. Analysts forecast that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Hedge Funds Weigh In On Scholar Rock

Several hedge funds have recently made changes to their positions in SRRK. Newbridge Financial Services Group Inc. acquired a new stake in shares of Scholar Rock in the fourth quarter valued at approximately $132,000. StoneCrest Wealth Management Inc. grew its position in Scholar Rock by 24.7% in the fourth quarter. StoneCrest Wealth Management Inc. now owns 59,003 shares of the company’s stock valued at $2,494,000 after purchasing an additional 11,671 shares in the last quarter. Tema Etfs LLC increased its stake in Scholar Rock by 6.6% in the 4th quarter. Tema Etfs LLC now owns 9,899 shares of the company’s stock valued at $436,000 after buying an additional 616 shares during the last quarter. Three Seasons Wealth LLC increased its stake in Scholar Rock by 2.1% in the 4th quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock valued at $483,000 after buying an additional 222 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in Scholar Rock by 602.4% during the 4th quarter. SG Americas Securities LLC now owns 84,349 shares of the company’s stock worth $3,716,000 after buying an additional 72,341 shares in the last quarter. 91.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

SRRK has been the subject of several recent analyst reports. Citigroup began coverage on Scholar Rock in a report on Friday, January 9th. They issued a “buy” rating and a $55.00 price target for the company. Barclays increased their target price on Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $50.00 price target on shares of Scholar Rock in a research note on Friday, November 14th. Bank of America assumed coverage on shares of Scholar Rock in a report on Thursday, October 9th. They issued a “buy” rating and a $53.00 price target for the company. Finally, JPMorgan Chase & Co. raised their price objective on shares of Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $50.14.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).